Related Experiment Video

Updated: Nov 17, 2025

Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery
09:12

Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery

Published on: March 27, 2018

9.7K

A retrospective study on the short-term effect of high-dose spironolactone (80 mg/d) on chronic congestive heart

Pan Tao1, Tu Zhitao2, Liu Jiming3

  • 1Department of Critical Medicine.

Medicine
|February 17, 2021
PubMed

Insights

High-dose spironolactone (80 mg/d) significantly improved cardiac function in chronic congestive heart failure (CHF) patients. This dose rapidly reduced biomarkers, enhanced exercise tolerance, and improved clinical outcomes compared to a lower dose.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Chronic congestive heart failure (CHF) remains a significant health concern.
  • Spironolactone is a key medication in managing CHF, but optimal dosing is continuously studied.

Purpose of the Study:

  • To evaluate the short-term efficacy and impact of a high dose of spironolactone (80 mg/d) on chronic congestive heart failure (CHF).

Main Methods:

  • A retrospective analysis of 211 CHF patients was conducted.
  • Patients were divided into low-dose (40 mg/d) and high-dose (80 mg/d) spironolactone groups.
  • Key indicators including B-type natriuretic peptide (BNP), NT-pro BNP, echocardiographic parameters, 6-minute walking test (6MWT), and NYHA class were assessed.

Main Results:

  • Both doses increased blood potassium within normal limits.
  • High-dose spironolactone significantly reduced BNP, NT-pro BNP, LVEDD, LVEDV, and NYHA class compared to the low-dose group.
  • The high-dose group also showed significant improvements in LVEF, 6-MWT, and overall effective treatment rate.

Conclusions:

  • High-dose spironolactone (80 mg/d) demonstrates superior short-term efficacy in CHF management.
  • It rapidly reduces cardiac biomarkers, enhances exercise capacity, and improves cardiac function and clinical status more effectively than a 40 mg/d dose.

More Related Videos

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

1.4K
5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

24.0K

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
610
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
666
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
107
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
89
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
557
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
217